product name
|
atorvastatin
|
chemical name
|
1h-pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βr,δr)-rel-;1h-pyrrole-1-heptanoic acid;(3s,5s)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid;atorvastatin;atorvastatin(relative)
|
cas no.
|
110862-48-1
|
formula
|
c33h35fn2o5
|
color
|
white powder
|
application
|
to treat high cholesterol, and to lower the risk of stroke, heart attack, or other heart complications in people with type 2 diabetes, coronary heart disease, or other risk factors
|
1, about atorvastatin
atorvastatin is in a group of drugs called hmg coa reductase inhibitors, or "statins." atorvastatin reduces levels of "bad" cholesterol (low-density lipoprotein, or ldl) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or hdl).
atorvastatin is used to treat high cholesterol, and to lower the risk of stroke, heart attack, or other heart complications in people with type 2 diabetes, coronary heart disease, or other risk factors.
atorvastatin is used in adults and children who are at least 10 years old.
2, dose
usual adult dose for prevention of cardiovascular disease:
initial dose: 10 mg to 80 mg orally once a day.
the initial dosage of atorvastatin recommended for this patient in the prevention of cardiovascular disease is 10 mg to 80 mg orally once a day. atorvastatin may be administered at any time of the day without regard for meals.
dose adjustments should be made at intervals of 2 to 4 weeks.
studies have demonstrated that treatment with atorvastatin is associated with significant reductions in the risk of cardiovascular endpoints and stroke in various patient populations for both primary and secondary prevention.
for primary prevention, atorvastatin treatment was effective in hypertensive patients with normal or mildly elevated cholesterol levels as well as in patients with type ii diabetes. patients had relatively low cholesterol levels at baseline in both trials; however, treatment with atorvastatin still resulted in significant reductions in cardiovascular outcomes and stroke.
for secondary prevention, intensive lipid lowering therapy with atorvastatin 80 mg/day was associated with significant incremental clinical benefit beyond therapy with 10 mg/day in patients with stable coronary heart disease. it was also shown to significantly reduce the risk of clinical outcomes in coronary heart disease patients versus usual medical care.
usual atorvastatin adult dose for hyperlipidemia:
initial dose: 10, 20 or 40 mg orally once a day. the 40 mg starting dose is recommended for patients who require a reduction in ldl-cholesterol of more than 45%.
dose adjustments should be made at intervals of 2 to 4 weeks.